Skip to main content Accessibility help
×
Home

Treatment of Alzheimer's Disease: Hopes and Reality

  • S. Gauthier (a1), L. Gauthier (a1), R. Bouchard (a1), R. Quirion (a1) and S. Sultan (a1)...

Abstract:

The relative failure of symptomatic therapeutic trials for Alzheimer's disease using non-selective cholinergic agonists brings about the need for longitudinal studies with parallel designs aimed at disease stabilization, using trophic substances or amyloid suppressors.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment of Alzheimer's Disease: Hopes and Reality
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment of Alzheimer's Disease: Hopes and Reality
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment of Alzheimer's Disease: Hopes and Reality
      Available formats
      ×

Copyright

Corresponding author

McGill Centre for Studies in Aging, 1650 Cedar Avenue, Room 10830 L.H., Montreal, Quebec, Canada H3G 1A4

References

Hide All
1.Gauthier, S, Leblanc, R, Quirion, R, et al. Transmitter-replacement therapy in Alzheimer’s disease using intracerebro-ventricular infusions of receptors agonists. Can J Neurol Sci 1986; 13: 394402.
2.Quirion, R, Martel, JC, Robitaille, Y, et al. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 1986; 13: 503510.
3.Doucette, R, Fisman, M, Hachinski, NC, et al. Cell loss from the Nucleus Basalis of Meynert in Alzheimer’s disease. Can J Neurol Sci 1986; 13: 435440.
4.Etienne, P, Dastoor, D, Gauthier, S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurology 1981; 31: 15521554.
5. Harbaugh, RE, Reeder, TM, (Leblanc, R), et al. Intracerebroventricular bethanechol chloride infusion in Alzheimer’s disease. J Neurosurg 1989; 71: 481486.
6.Gauthier, S, Bouchard, R, Lamontagne, A, et al. Tetrahydroamino-acridine-lecithin combination treatment in patients with intermediate - stage Alzheimer’s disease. N Engl J Med 1990; 322: 12721276.
7.Lavori, PW, Louis, TA, Bailar, JC, et al. Designs for experiments - parallel comparisons of treatment. N Engl J Med 1983; 309: 12911298.
8.Louis, TA, Lavori, PW, Bailar, JC, et al. Cross-over and self controlled designs in clinical research. N Engl J Med 1984; 310: 2431.
9.Katzman, R, Brown, T, Thai, LJ, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer’s disease. Ann Neurol 1988; 24: 384389.
10.Stern, Y, Hesdorffer, D, Sano, M, et al. Measurement and prediction of functional capacity in Alzheimer’s disease. Neurology 1990; 40: 814.
11.Kaszniak, AW, Wilson, RS, Fox, JH, et al. Cognitive assessment in Alzheimer’s disease: Cross-sectional and longitudinal perspectives. Can J Neurol Sci 1986; 13: 420423.
12.Huff, FJ, Belle, SH, Shin, YK, et al. Prevalence and prognostic value of neurologic abnormalities in Alzheimer’s disease. Dementia 1990; 1: 3240.
13.Crapper, McLachlan D, Dalton, AJ, Galin, H, et al. Alzheimer’s disease: clinical course and cognitive disturbances. Acta Neurol Sand 1984; 60 suppl 99: 8388.
14.Dastoor, D, Cole, MG. The course of Alzheimer’s disease: an uncontrolled longitudinal study. J Clin Exp Gerontology 1985–86; 7: 289299.
15.Uhlamnn, RF, Larson, EB, Buchner, DM. Correlations of Mini-Mental State and Modified Dementia Rating Scale to measure transitional health status in dementia. J Gerontology 1987; 42: 3336.
16.Gauthier, L, Gauthier, S. Assessment of functional changes in Alzheimer’s disease. Neuroepidemiology 1990; 9: 183188.
17.Grady, CL, Haxby, JV, Horwitz, B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychology 1988; 10: 576596.
18.Botwinick, J, Storandt, M, Berg, L. A longitudinal behavioral study of senile dementia of the Alzheimer type. Arch Neurol 1986; 43: 11241127.
19.The Parkinson Study Group. Effect of Deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 13641371.
20.Drachman, DA, O’Donell, BF, Lew, RA, et al. The prognosis in Alzheimer’s disease: how far rather than how fast best predicts the course. Arch Neurol 1990; 47: 851856.

Treatment of Alzheimer's Disease: Hopes and Reality

  • S. Gauthier (a1), L. Gauthier (a1), R. Bouchard (a1), R. Quirion (a1) and S. Sultan (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed